Medicare Coverage of Ozempic Could Change Weight Loss Treatment Options—CEO

Eli Lilly said Medicare’s new decision to cover GLP‑1 obesity medications will materially expand the addressable market for its upcoming oral obesity pill, orforglipron, which the company expects to fully launch in Q2 with Medicare coverage “immediately following that launch,” CEO Dave Ricks said. With CDC figures showing 41.9% of U.S. adults obese and Lilly estimating 20–30 million obese Medicare beneficiaries, plus new copay caps near $50/month and current U.S. list prices (KFF: Ozempic $936/mo; Wegovy $1,349/mo), the move could substantially boost revenue prospects for Lilly while raising fiscal and safety questions about long‑term Medicare spending on GLP‑1s.

Analysis

Market structure: Medicare coverage (copay ~$50/month vs list $936–$1,349) converts a high-price, low-access product into a high-volume market; Eli Lilly (LLY) launching orforglipron in Q2 stands to gain immediate volume and formulary access while Novo Nordisk (NVO) faces pricing pressure and share erosion. PBMs, retail pharmacies (WBA), and insurers (CVS, UNH) become pivotal intermediaries — short-term margin hit from higher drug spend may be offset by longer-term reductions in diabetes morbidity. Cross-assets: incremental Medicare outlays (~20–30M obese beneficiaries) add fiscal pressure that favors higher long-term Treasury yields and raises healthcare insurer volatility; FX/commodities impact is minimal.

Risk assessment: Tail risks include CMS reversal, federal/state price caps, or a major safety signal prompting black-box warnings; any of these could truncate demand within weeks. Time horizons: immediate (days) — CMS/contract updates; short (weeks–months) — Q2 launch, first Medicare coverage mechanics; long (years) — chronic-use economics, potential >$100B spend scenario. Hidden dependencies: PBM rebate flows, Part D benefit design, off-label prescribing and supply constraints could materially change net revenue. Key catalysts: CMS final guidance, state Medicaid adoption, LLY launch data, and head-to-head real-world efficacy reports over 3–12 months.

Trade implications: Direct long LLY exposure ahead of Q2 is sensible (see decisions) while NVO is the primary relative short; insurers/PBMs are mixed — hedge short-term drug-cost exposure but consider selective long on UNH if utilization-management reduces net long-term claims. Options: use limited-cost call spreads on LLY into Q3 and protective puts on NVO into the same window. Entry/exit: initiate trades 4–8 weeks pre-launch, reprice/trim on CMS confirmation or first Medicare utilization print (90–180 days).

Contrarian angles: Consensus assumes perpetual chronic use; if meaningful discontinuation occurs due to side effects or strict utilization controls, TAM collapses and prices could spike back up — that would favor NVO over LLY. Historical analog: rapid uptake then rationing (HCV antivirals) shows policymakers can pivot to control spend. Watch for PBM steering, biosimilar competition, or political backlash — if NVO declines >8% vs LLY, consider flipping pair trade.

Key Decisions for Investors

• Establish a 2–3% net long position in Eli Lilly (LLY) equity ahead of the expected Q2 orforglipron launch; target entry 4–8 weeks pre-launch, take profits on a 20–25% move or reassess after 90 days of Medicare utilization data.
• Implement a relative-value pair: long LLY 2% / short NVO 1–1.5% to capture expected share shift and price compression; tighten stop if LLY underperforms NVO by >8% over any 30-day window.
• Buy a limited-cost LLY call spread (size = 0.5–1% portfolio risk): purchase ATM calls and sell 10–15% OTM calls expiring 3–6 months out (enter 4–6 weeks pre-launch) to capture upside while capping premium spend.
• Hedge broader portfolio exposure to higher Medicare drug spend by buying 2–3% protection in long-dated (6–12 month) puts on large pharmacy/retail (WBA) or selling short-term call overwrites on existing insurer longs (UNH, CVS) if CMS final rule increases formulary pass-throughs; re-evaluate on CMS and PBM announcements within 30–60 days.